- Headquarters: Cupertino, CA
- Founded: 1998
- durect.com
Durect reports top-line results from the PERSIST Phase 3 Trial of POSIMIR (SABER-Bupivacaine) did not meet primary efficacy endpoint
- DURECT reported that PERSIST, the Phase 3 clinical trial for POSIMIR (SABER-Bupivacaine), did not meet its primary efficacy endpoint of reduction in pain on movement over the first 48 hours after surgery as compared to standard bupivacaine HCl. While results trended in favor of POSIMIR versus the comparator, they did not achieve statistical significance. POSIMIR is an investigational drug candidate being developed for the treatment of post-surgical pain.
- "We are very surprised and disappointed by these results, which we will be trying to understand more fully over the coming weeks." In May 2017, DURECT and Sandoz AG (NVS) entered into a license agreement to develop and market POSIMIR in the United States, and the agreement became effective in June 2017.
Description
Durect Corporation is a biopharmaceutical company with research and development programs. The Company's products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic. The Company's ALZET product line consists of miniature, implantable osmotic pumps and accessories used for experimental research in mice, rats and other laboratory animals. The Company also manufactures and sells osmotic pumps used in laboratory research and design; and develops and manufactures a range of standard and custom biodegradable polymers and excipients for pharmaceutical and medical device clients for use as raw materials in their products.
Key stats and ratios
| Q2 (Jun '17) | 2016 | |
| Net profit margin | -229.84% | -246.05% |
| Operating margin | -216.83% | -230.76% |
| EBITD margin | - | -227.79% |
| Return on average assets | -95.91% | -79.08% |
| Return on average equity | -5651.82% | -297.22% |
| Employees | 98 |
No comments:
Post a Comment